With 2.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 11.0 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7299 whereas the lowest price it dropped to was $1.55. The 52-week range on SLXN shows that it touched its highest point at $122.02 and its lowest point at $0.57 during that stretch. It currently has a 1-year price target of $9.00. Beta for the stock currently stands at 0.02.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLXN was up-trending over the past week, with a rise of 170.69%, but this was down by -21.89% over a month. Three-month performance dropped to -40.67% while six-month performance fell -98.51%. The stock lost -98.28% in the past year, while it has lost -21.89% so far this year.
Float and Shares Shorts:
At present, 4.00 million SLXN shares are outstanding with a float of 2.10 million shares on hand for trading. On 2024-11-15, short shares totaled 35842.0, which was 223.99999999999997 higher than short shares on 1728950400. In addition to Ms. Mirit Horenshtein Hadar as the firm’s EVP of Finance Affairs, CFO & Secretary, Dr. Mitchell Shirvan M.B.A., Ph.D. serves as its Chief Scientific & Development Officer.
Institutional Ownership:
Through their ownership of 0.08151 of SLXN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, SLXN reported revenue of $0.0 and operating income of -$8036000.0. The EBITDA in the recently reported quarter was -$9030000.0 and diluted EPS was -$2.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SLXN analysts setting a high price target of 9.0 and a low target of 9.0, the average target price over the next 12 months is 9.0. Based on these targets, SLXN could surge 473.25% to reach the target high and rise by 473.25% to reach the target low. Reaching the average price target will result in a growth of 473.25% from current levels.
Analysts have provided yearly estimates in a range of -$1.25 being high and -$1.25 being low. For SLXN, this leads to a yearly average estimate of -$1.25. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.